Thursday, October 15, 2026
ExploreSearch
Via News
MarketCommodities

Lumber Futures Bullish Momentum With A 14% Rise In The Last 21 Sessions

Lumber Futures Bullish Momentum With A 14% Rise In The Last 21 Sessions

(VIANEWS) - Lumber (LBS) has been up by 14.7% for the last 21 sessions. At 11:50 EST on Tuesday, 21 March, Lumber (LBS) is $440.00.

Volume

Today's last reported volume for Lumber is 104, 99.99% below its average volume of 19007621.96.

Volatility

Lumber's last week, last month's, and last quarter's current intraday variation average was 16.95%, 6.66%, and 5.42%, respectively.

Lumber's highest amplitude of average volatility was 16.95% (last week), 7.32% (last month), and 5.42% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Lumber's commodity is considered to be oversold (<=20).

More news about Lumber (LBS).

Categories

MarketCommodities

Tags

CommodityCommoditiesFuturesLBSLumberPrice UpCommodities Price UpCommodities Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com